Latest Pharma-VC Experiment: Arteaus Gets $18M For Migraine Drug Licensed From Lilly

Atlas Venture and OrbiMed Advisors have launched a virtual company to support development of a single asset, which Lilly can buy back after a Phase II trial.

More from Archive

More from Pink Sheet